Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, August 26, 2021
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
[ Thu, Aug 26th 2021
] - WOPRAI
Wed, August 25, 2021
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
[ Wed, Aug 25th 2021
] - WOPRAI
Vikram Purohit Downgraded (TBPH) to Sell and Decreased Target to $14 on, Aug 25th, 2021
Vikram Purohit of Morgan Stanley, Downgraded "Theravance Biopharma, Inc." (TBPH) to Sell and Decreased Target from $27 to $14 on, Aug 25th, 2021.
Vikram has made no other calls on TBPH in the last 4 months.
There are 4 other peers that have a rating on TBPH. Out of the 4 peers that are also analyzing TBPH, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Marc Frahm of "Cowen & Co." Downgraded from Buy to Hold and Decreased Target to $14 on, Tuesday, August 24th, 2021
These are the ratings of the 3 analyists that currently disagree with Vikram
- Douglas Tsao of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $21 on, Tuesday, August 24th, 2021
- Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $29 on, Tuesday, August 24th, 2021
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $18 on, Tuesday, August 24th, 2021
